Enveric Biosciences, Inc.
ENVB
$1.69
$0.095.63%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.09% | -16.08% | 19.70% | -2.34% | -27.88% |
| Depreciation & Amortization | -54.07% | -52.12% | -52.36% | -52.83% | -5.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.34% | -30.87% | -10.05% | 32.73% | -11.70% |
| Operating Income | 25.34% | 30.87% | 10.05% | -32.73% | 11.70% |
| Income Before Tax | 25.24% | 30.29% | 10.09% | -34.04% | 11.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.24% | 30.44% | 10.09% | -34.04% | 11.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.24% | 30.44% | 10.09% | -34.04% | 11.07% |
| EBIT | 25.34% | 30.87% | 10.05% | -32.73% | 11.70% |
| EBITDA | 24.24% | 30.31% | 8.25% | -36.73% | 11.93% |
| EPS Basic | 92.58% | 89.37% | 74.91% | 73.88% | 86.80% |
| Normalized Basic EPS | 92.58% | 94.21% | 86.12% | 73.88% | 86.79% |
| EPS Diluted | 92.58% | 89.37% | 74.91% | 73.88% | 86.80% |
| Normalized Diluted EPS | 92.58% | 94.21% | 86.12% | 73.88% | 86.79% |
| Average Basic Shares Outstanding | 908.28% | 1,103.83% | 547.11% | 412.56% | 574.77% |
| Average Diluted Shares Outstanding | 908.28% | 1,103.83% | 547.11% | 412.56% | 574.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |